Study on the application of Chinese medicine directional dialysis in elderly patients with diabetic high-risk feet with Qi deficiency and blood evidence

注册号:

Registration number:

ITMCTR2025001073

最近更新日期:

Date of Last Refreshed on:

2025-05-28

注册时间:

Date of Registration:

2025-05-28

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

中医定向透药在老年糖尿病高危足患者气虚血证的应用研究

Public title:

Study on the application of Chinese medicine directional dialysis in elderly patients with diabetic high-risk feet with Qi deficiency and blood evidence

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中医定向透药在老年糖尿病高危足患者气虚血证的应用研究

Scientific title:

Study on the application of Chinese medicine directional dialysis in elderly patients with diabetic high-risk feet with Qi deficiency and blood evidence

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李美兰

研究负责人:

马力凤

Applicant:

Meilan Li

Study leader:

Lifang Ma

申请注册联系人电话:

Applicant telephone:

+86 198 1756 3023

研究负责人电话:

Study leader's telephone:

+86 192 6581 6211

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

19817563023@163.com

研究负责人电子邮件:

Study leader's E-mail:

2169336263@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市浦东新区高桥镇大同路358号

研究负责人通讯地址:

上海市浦东新区高桥镇大同路358号

Applicant address:

No.358 Datong Road Gaoqiao Town Pudong New Area Shanghai China

Study leader's address:

No.358 Datong Road Gaoqiao Town Pudong New Area Shanghai China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大理大学

Applicant's institution:

Dali University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-7th-HIRB-027

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海市第七人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Seventh People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/1/21 0:00:00

伦理委员会联系人:

张春燕

Contact Name of the ethic committee:

Chunyan Zhang

伦理委员会联系地址:

上海市浦东新区高桥镇大同路 358号1号楼辅楼 203 室

Contact Address of the ethic committee:

Room 203 Auxiliary Building Building 1 No. 358 Datong Road Gaogaoqiao Town Pudong New Area Shanghai China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 5867 0561

伦理委员会联系人邮箱:

Contact email of the ethic committee:

2865067429@qq.COM

研究实施负责(组长)单位:

上海市第七人民医院

Primary sponsor:

Shanghai Seventh People's Hospital

研究实施负责(组长)单位地址:

上海市浦东新区高桥镇大同路 358号

Primary sponsor's address:

No.358 Datong Road Gaoqiao Town Pudong New Area Shanghai China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第七人民医院

具体地址:

上海市浦东新区高桥镇大同路 358号

Institution
hospital:

Shanghai Seventh People's Hospital

Address:

No.358 Datong Road Gaoqiao Town Pudong New Area Shanghai China

经费或物资来源:

自筹

Source(s) of funding:

self-finance

研究疾病:

糖尿病足

研究疾病代码:

Target disease:

diabetic foot

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究基于子午流注理论,选择经络最为活跃的时间段进行中医定向透药治疗,以增强治疗效果。根据具体药方和药物成分的吸收特点,合理安排治疗时间和穴位,确保药物能够充分发挥作用,以期为糖尿病高危足患者改善症状、缓解疼痛提供帮助。

Objectives of Study:

Based on the theory of meridian flow injection this study selects the time period when the meridians are most active to carry out TCM directed drug transmission therapy in order to enhance the therapeutic effect. According to the absorption characteristics of specific prescriptions and drug components the treatment time and acupoints were reasonably arranged to ensure that the drugs could give full play to their effects with a view to providing assistance to diabetic patients with high-risk feet in terms of improving symptoms and relieving pain.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)明确2型糖尿病病史,病程≥10年,肌电图符合IWGDF糖尿病高危足诊断患者;(2)符合上述西医诊断及中医证候诊断标准者;(3)年龄≥65岁,双下肢无伤口、无皮肤病;(4)患者对研究知情同意,且签署知情同意书。

Inclusion criteria

(1) patients with a clear history of type 2 diabetes mellitus with a disease duration of ≥10 years and EMG consistent with the IWGDF diagnosis of diabetic high-risk foot; (2) those who met the above diagnostic criteria for Western medicine diagnosis and traditional Chinese medicine evidence; (3) those who were aged ≥60 years and had no wounds or skin diseases on both lower limbs; and (4) patients who gave informed consent to the study and had signed the informed consent form.

排除标准:

(1)其他原因引起的周围神经病变者;(2)急性脑出血等急性病患者;(3)患有精神类疾病不能配合检查及治疗患者、传染病患者;(4)安装心脏起搏器、体内有金属植入患者;(5)妊娠妇女;(6)对所用定向透药中的中药成分过敏者及严重过敏体质者;(7)有出血倾向及出血性疾病的患者。

Exclusion criteria:

(1) patients with peripheral neuropathy caused by other reasons; (2) patients with acute diseases such as acute cerebral hemorrhage; (3) patients with mental illnesses who cannot cooperate with the examination and treatment and patients with infectious diseases; (4) patients with cardiac pacemakers and metal implants in the body; (5) pregnant women; (6) patients who are allergic to the traditional Chinese medicine components in the directional transdermal medicines used and those who have severe allergies; (7) patients with a tendency to hemorrhage and bleeding disorders; and (8) patients who have a tendency to hemorrhage and bleeding disorders. (7) Patients with bleeding tendency and bleeding disorders.

研究实施时间:

Study execute time:

From 2025-01-21

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2025-06-30

To      2025-12-21

干预措施:

Interventions:

组别:

干预组

样本量:

38

Group:

intervention group

Sample size:

干预措施:

每天巳时(9:00)进行定向透药治疗,穴位选取足三里、三阴交、阴陵泉,频率为一天一次,每次30分钟。

干预措施代码:

Intervention:

Every day at the sixth hour (9:00) for directional drug delivery therapy, acupoints selected foot Sanli, Sanyinjiao, Yinlingquan, the frequency of once a day, each time 30 minutes.

Intervention code:

组别:

对照组

样本量:

38

Group:

control group

Sample size:

干预措施:

常规治疗:根据《中国2型糖尿病防治指南》(2019年版)指导患者常规用药。进行糖尿病治疗:糖尿病主要采取胰岛素和口服降糖药降低血糖。

干预措施代码:

Intervention:

Routine treatment: patients are instructed to take routine medication according to the Chinese Guidelines for the Prevention and Control of Type 2 Diabetes Mellitus (2019 edition). Conduct diabetes treatment: diabetes is mainly taken insulin and oral hypoglycaemic drugs to lower blood sugar.

Intervention code:

样本总量 Total sample size : 76

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第七人民医院

单位级别:

三甲

Institution/hospital:

Shanghai Seventh People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

温控血流

指标类型:

主要指标

Outcome:

Temperature controlled blood flow

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

多伦多临床评分

指标类型:

次要指标

Outcome:

Toronto clinical scoring system

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经传导速度

指标类型:

次要指标

Outcome:

nerve conduction velocity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

主要指标

Outcome:

Chinese Medicine Criteria Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

踝肱指数

指标类型:

次要指标

Outcome:

ankle-brachial index (ABI)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

震动感觉阈值

指标类型:

次要指标

Outcome:

vibration threshold

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 65
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

选取2025年6月-2025年12月在上海市第七人民医院内分泌科诊断为糖尿病周围神经病的住院患者。对符合纳排标准的患者按入院先后顺序进行编号。采用《医学统计学》(第3版)中的随机数字表法随机分组所纳入的患者。具体方法如下,在随机数字表中随机选取任意行、列依次读取数字,将其对应患者编号。将读取的随机数字除以组数2,能够整除为观察组,余数为1为对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Inpatients with diabetic peripheral neuropathy diagnosed in the Department of Endocrinology of Shanghai Seventh People's Hospital from January 2025 to December 2025 were selected. Patients who met the criteria for natriuresis were numbered according to the order of admission. The included patients were randomly grouped using the random number table method in Medical Statistics (3rd edition). The method was as follows: read the numbers in any randomly selected rows and columns of the random number table in sequence and number them corresponding to the patients. The number of random numbers read was divided by the number of groups 2 which was able to be divided by the whole for the observation group and the remainder was 1 for the control group.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above